HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Frondoza, C. G. Articles by Goble, J. C. Search for Related Content PubMed PubMed Citation Articles by Frondoza, C. G. Articles by Goble, J. C.

Metabolism of Guanido-Labeled (C-14)Arginine in Rats, Mice, and Man

The Johns Hopkins University, School of Medicine, Baltimore, Maryland
Division of Research Services, National Institutes of Health, Department of Health, Education and Welfare, Bethesda, Maryland

Correspondence: For reprints contact: Carmelita G. Frondoza, The Johns Hopkins Medical Institutions, Oncology Center, 600 N. Wolfe St., Baltimore, MD 21205.

ABSTRACT

[16-¹⁴C]arginine, injected intraperitoneally into normal rats, was cleared from the plasma with biphasic decay kinetics. Urinary excretion was efficient (32% of the 25-µCi dose within the first 24 hr) with no preferential tissue retention. In mice, the effective duration of the radiotracer's availability for protein biosynthesis was less than 30 min.

When the tracer was administered i.v. to patients with multiple myeloma, it was similarly cleared from the plasma with biphasic kinetics, and was excreted rapidly in the urine (22% of the dose with in the first 24 hr). In patients, the guanido-tagged arginine labeled only tumor M component, and the labeling was most intense in patients who had far advanced disease. Estimated radiation dose to humans from a 100-µCi injection was 10 mrads. These studies demonstrate the feasibility of in vivo labeling with [6-¹⁴C]arginine, with minimal radiation hazard, thus providing a simple, sensitive, and specific method for monitoring the synthesis of the plasma-cytoma M component in patients with multiple myeloma.